RecruitingInterventional

Feasibility and Preliminary Efficacy of a Digital Story Intervention to Facilitate Decision-Making in Patients With Myeloid Cancers Considering Allogeneic Hematopoietic Cell Transplantation

NCT ID: NCT07263074Sponsor: University of RochesterLast updated: 2026-03-30

Summary

This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \[CHORDS\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).

Detailed description

Our proposed intervention is Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories (CHORDS), which includes: 1) real-life digital stories of individuals with similar experiences who previously underwent consultation for allogeneic hematopoietic cell transplantation and their caregivers and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling. Together, they help patients reflect on their values and prioritize their own needs and goals, enhance emotional awareness, and gain experiential knowledge from peers to better understand the real-life implications of treatment risks and benefits.

Arms & interventions

OtherCHORDS
The CHORDS intervention consists of 1) digital stories created by individuals who previously underwent consultation for alloHCT and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling (BWS).

Outcome measures

Primary

Percentage of Participants Retained (Feasibility - Retention Rate)
Feasibility will be assessed based on the percentage of enrolled participants who complete both the intervention and post-intervention secondary outcome assessments. The number of participants who complete all study procedures will be divided by the total number enrolled to calculate the retention rate. Higher percentages indicate greater feasibility.
Time frame: From enrollment (Day -30 to Day 0) to 2 weeks post-alloHCT office visit (Day 9-19)

Secondary

Mean Change in Decisional Engagement Scale Score
Time frame: Baseline (Day -30 to Day 0) to 2 weeks post-alloHCT office visit (Day 9-19)
Mean Change in Decisional Conflict Scale Score
Time frame: Baseline (Day -30 to Day 0) to 2 weeks post-alloHCT office visit (Day 9-19)
Mean Change in Distress Thermometer Score
Time frame: Baseline (Day -30 to Day 0) to 2 weeks post-alloHCT office visit (Day 9-19)

Eligibility criteria

Sex: AllAge: 21 Years and olderHealthy volunteers: No

Patients Inclusion criteria: 1. Age \>21 years old 2. Diagnosis of myeloid cancer (AML, MDS, myelofibrosis, CML, or MDS/MPN) 3. Being considered for alloHCT 4. Able to provide informed consent 5. Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated. Exclusion criteria 1) Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures Caregivers Inclusion criteria: 1. Age \>18 years old 2. Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters." 3. Caregiver may be paid/professional or informal caregiver 4. Able to provide informed consent 5. Able to speak English Exclusion Criteria: 1\) None Hematologists Inclusion criteria: 1\) Hematologists of the patients who agree to enroll on the study who are part of Wilmot Cancer Institute. Exclusion criteria 1\) None

Study locations (1)

University of Rochester

Rochester, New York, 14642

Recruiting

Rachel Rodenbach · Contact

585-275-5830 rachel_rodenbach@urmc.rochester.edu

Rachel Rodenbach · Principal Investigator